A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies

Brief description of study

If you have been diagnosed with gastroesophageal, stomach, or gastroesophageal junction (GEJ) cancers, you may qualify for this clinical trial. The goal of this phase II study is to determine whether combination therapy of lenvatinib ( LENVIMA®) with pembrolizumab ( KEYTRUDA®) is safe and effective in treating metastatic gastroesophageal cancer that has progressed on first or subsequent line{s) therapies. This study will also determine what effects lenvatinib and pembrolizumab has on you and your disease.

Clinical Study Identifier: s17-00626
ClinicalTrials.gov Identifier: NCT03321630

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.